Satvat Ali J.

SEC source: 0001470831-26-000625 · wk-form4_1782338712.xml · derivative · entry 2

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,277

Underlying: Common Stock · 5,277 shares

Expires 2036-06-21

F3 · derivative.exercise_date: The shares underlying the stock option vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

SEC source: 0001470831-26-000625 · wk-form4_1782338712.xml · nonDerivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 169,983

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. The RSUs vest in full on June 22, 2027, subject to the Reporting Person's continued service on the Issuer's board of directors through the vesting date.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001610717-26-000206 · form4.xml · derivative · entry 2

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 60,000

Underlying: Common Stock · 60,000 shares

Expires 2036-06-05

F2 · derivative.exercise_date: The underlying shares vest and become exercisable as to 100% of the total number of the shares subject to the option on June 3, 2027, subject to the Reporting Person's continued service relationship with the Issuer on such vesting date.

SEC source: 0001610717-26-000206 · form4.xml · nonDerivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,000

F1 · shares: Constitute restricted stock units ("RSUs") for which the Reporting Person is entitled to receive one (1) share of Common Stock for each RSU upon vesting. 100% of the RSUs shall vest on the one year anniversary of June 3, 2026, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.

SEC source: 0000950170-25-089665 · ownership.xml · derivative · entry 2

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,425

Underlying: Common Stock · 8,425 shares

Expires 2035-06-19

F3 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 20, 2025, such that all of the underlying shares will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

SEC source: 0000950170-25-089665 · ownership.xml · nonDerivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,993

F1 · kind: Grant of restricted stock units ("RSUs") under the Issuer's 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan. One-third of the RSUs will vest each year after June 20, 2025, such that all of the units will be vested on June 20, 2028, subject to the Reporting Person's continued service on the Issuer's board of directors.

F2 · price: Each RSU represents a contingent right to receive one share of the Issuer's Common Stock.

SEC source: 0001610717-25-000222 · form4.xml · derivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 112,000

Underlying: Common Stock · 112,000 shares

Expires 2035-06-12

F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the one year anniversary of June 11, 2025, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.

SEC source: 0000950170-24-141676 · ownership.xml · derivative · entry 6

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 39,851 shares

Expires 2030-05-27

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The stock option was fully vested and exercisable on the date of issuance by the Issuer as of January 26, 2021.

SEC source: 0000950170-24-141676 · ownership.xml · derivative · entry 5

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 39,851 shares

Expires 2029-06-12

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The stock option was fully vested and exercisable on the date of issuance by the Issuer as of January 26, 2021.

SEC source: 0000950170-24-141676 · ownership.xml · derivative · entry 4

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 79,702 shares

Expires 2028-07-01

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The stock option was fully vested and exercisable on the date of issuance by the Issuer as of January 26, 2021.

SEC source: 0000950170-24-141676 · ownership.xml · nonDerivative · entry 3

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 159,404

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-141676 · ownership.xml · nonDerivative · entry 2

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,553

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-141676 · ownership.xml · nonDerivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 79,702

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0000950170-24-077450 · ownership.xml · derivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,014

Underlying: Common Stock · 26,014 shares

Expires 2034-06-20

F1 · derivative.exercise_date: One-third of the shares underlying the stock option will vest each year after June 21, 2024, such that all of the underlying shares will be vested on June 21, 2027, subject to the Reporting Person's continued service on the board of directors of the Issuer.

SEC source: 0001209191-23-039391 · doc4.xml · derivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 51,501

Underlying: Common Stock · 51,501 shares

Expires 2033-06-21

F1 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 21, 2024; thereafter, 1/3rd of the underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on June 21, 2026, subject to the optionee's continued service on the Board of Directors of the Company.

SEC source: 0001209191-22-039262 · doc4.xml · derivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 104,921

Underlying: Common Stock · 104,921 shares

Expires 2032-06-22

F1 · derivative.exercise_date: 1/3rd of the shares underlying the option will vest on June 22, 2023; thereafter, 1/3rd of the remaining underlying shares will vest on an annual basis, so that all of the underlying shares will be vested on the June 22, 2025, subject to the optionee's continued service on the Board of Directors of the Company.

SEC source: 0000899243-21-025414 · doc4.xml · derivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 38,895

Underlying: Common Stock · 38,895 shares

Expires 2031-06-16

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments after June 17, 2021, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date.

SEC source: 0000899243-21-003676 · doc4.xml · derivative · entry 3

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,702

Underlying: Common Stock · 79,702 shares

Expires 2028-07-01

F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among Eidos Therapeutics, Inc. ("Eidos"), the Issuer, Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of the Issuer ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of the Issuer ("Merger Sub II"), Merger Sub was merged with and into Eidos, with Eidos continuing as the surviving corporation and immediately thereafter, Eidos was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). The option became fully vested immediately prior to the Effective Time.

F2 · derivative.exercise_date: (Continued from Footnote 1) At the Effective Time, each such option was cancelled, assumed by the Issuer and replaced with an option to purchase 1.85 shares of the Issuer's common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such stock option is subject to the same terms and conditions applicable to the Eidos option immediately prior to the Effective Time.

SEC source: 0000899243-21-003676 · doc4.xml · derivative · entry 2

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,851

Underlying: Common Stock · 39,851 shares

Expires 2029-06-12

F3 · derivative.exercise_date: The stock option was fully vested. At the Effective Time, each such option was cancelled, assumed by the Issuer and replaced with an option to purchase 1.85 shares of the Issuer's common stock at an exercise price per share of the Issuer's common stock equal to the exercise price per share of the Eidos option divided by 1.85. Such stock option is subject to the same terms and conditions applicable to the Eidos option immediately prior to the Effective Time.

SEC source: 0000899243-21-003676 · doc4.xml · derivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 39,851

Underlying: Common Stock · 39,851 shares

Expires 2030-05-27

F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among Eidos Therapeutics, Inc. ("Eidos"), the Issuer, Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of the Issuer ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of the Issuer ("Merger Sub II"), Merger Sub was merged with and into Eidos, with Eidos continuing as the surviving corporation and immediately thereafter, Eidos was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). The option became fully vested immediately prior to the Effective Time.

F2 · derivative.exercise_date: (Continued from Footnote 1) At the Effective Time, each such option was cancelled, assumed by the Issuer and replaced with an option to purchase 1.85 shares of the Issuer's common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such stock option is subject to the same terms and conditions applicable to the Eidos option immediately prior to the Effective Time.

SEC source: 0000899243-21-003647 · doc4.xml · derivative · entry 3

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 43,056 shares

Expires 2028-06-30

F1 · price: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). The option became fully vested immediately prior to the Effective Time.

F2 · price: (Continued from Footnote 1) At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time.

F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). The option became fully vested immediately prior to the Effective Time.

F2 · derivative.exercise_date: (Continued from Footnote 1) At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time.

SEC source: 0000899243-21-003647 · doc4.xml · derivative · entry 2

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,528 shares

Expires 2029-06-11

F3 · price: The option was fully vested. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time.

F3 · derivative.exercise_date: The option was fully vested. At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time.

SEC source: 0000899243-21-003647 · doc4.xml · derivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 21,528 shares

Expires 2030-05-27

F1 · price: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). The option became fully vested immediately prior to the Effective Time.

F2 · price: (Continued from Footnote 1) At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time.

F1 · derivative.exercise_date: Pursuant to the terms of the Agreement and Plan of Merger dated October 5, 2020 (the "Merger Agreement"), by and among the Issuer, BridgeBio Pharma, Inc. ("Parent"), Globe Merger Sub 1, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), and Globe Merger Sub II, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub II"), Merger Sub was merged with and into the Issuer, with the Issuer continuing as the surviving corporation and immediately thereafter, the Issuer was merged with and into Merger Sub II, with Merger Sub II continuing as the surviving corporation, effective as of January 26, 2021 (the "Effective Time"). The option became fully vested immediately prior to the Effective Time.

F2 · derivative.exercise_date: (Continued from Footnote 1) At the Effective Time, each such option was cancelled, assumed by Parent and replaced with an option to purchase 1.85 shares of Parent common stock at an exercise price per share of Parent common stock equal to the exercise price per share of the Issuer option divided by 1.85. Such Parent stock option is subject to the same terms and conditions applicable to the Issuer option immediately prior to the Effective Time.

SEC source: 0000899243-20-015302 · doc4.xml · derivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 112,422

Underlying: Common Stock · 112,422 shares

Expires 2030-06-01

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments after June 2, 2020, subject to the Reporting Person's continued service on the Issuer's Board of Directors through each such date.

SEC source: 0000899243-20-014539 · doc4.xml · derivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,528

Underlying: Common Stock · 21,528 shares

Expires 2030-05-27

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in a single installment on the earlier of (i) the first anniversary of the grant date, so that all of the underlying shares shall be vested on May 26, 2021, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service with the Issuer through the vesting date. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2018 Stock Option and Incentive Plan, as amended).

SEC source: 0001567619-20-001048 · doc1.xml · derivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2030-01-10

F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2020, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

SEC source: 0000899243-19-029344 · doc4.xml · derivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 82,878

Underlying: Common Stock · 82,878 shares

Expires 2029-12-11

F1 · derivative.exercise_date: The stock option vests and becomes exercisable in three annual installments after December 12, 2019, subject to the Reporting Person's continued service to the Issuer through each such date.

SEC source: 0000899243-19-019342 · doc4.xml · nonDerivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 24,575,501

F1 · ownership.nature: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-19-016953 · doc4.xml · derivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,528

Underlying: Common Stock · 21,528 shares

Expires 2029-06-11

F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in a single installment on the earlier of (i) the first anniversary of the grant date, so that all of the underlying shares shall be vested on June 12, 2020, or (ii) the Issuer's next annual meeting of stockholders, in each case subject to the Reporting Person's continued service with the Issuer through the vesting date. This option is subject to full acceleration of vesting with respect to all then-unvested shares upon the consummation of a Sale Event (as defined in the Issuer's 2018 Stock Option and Incentive Plan, as amended).

SEC source: 0000899243-19-015092 · doc4.xml · nonDerivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See Footnote

Disclosed balance after: 23,693,148

F1 · ownership.nature: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-19-002197 · doc4.xml · derivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2029-01-11

F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 11, 2019, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

SEC source: 0000899243-19-003700 · doc5.xml · nonDerivative · entry 7

Satvat Ali J. · CIK 0001621788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 22,589,300

F6 · price: Represents the weighted average purchase price of the shares purchased ranging from $13.86 to $14.00 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F1 · ownership.nature: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-19-003700 · doc5.xml · nonDerivative · entry 6

Satvat Ali J. · CIK 0001621788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 22,586,636

F5 · price: Represents the weighted average purchase price of the shares purchased ranging from $12.85 to $13.84 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F1 · ownership.nature: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-19-003700 · doc5.xml · nonDerivative · entry 5

Satvat Ali J. · CIK 0001621788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 22,548,647

F4 · price: Represents the weighted average purchase price of the shares purchased ranging from $13.34 to $14.48 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F1 · ownership.nature: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-19-003700 · doc5.xml · nonDerivative · entry 4

Satvat Ali J. · CIK 0001621788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 22,543,787

F3 · price: Represents the weighted average purchase price of the shares purchased ranging from $13.33 to $14.32 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F1 · ownership.nature: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-19-003700 · doc5.xml · nonDerivative · entry 3

Satvat Ali J. · CIK 0001621788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 22,507,473

F2 · price: Represents the weighted average purchase price of the shares purchased ranging from $12.79 to $13.55 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price.

F1 · ownership.nature: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-19-003700 · doc5.xml · nonDerivative · entry 2

Satvat Ali J. · CIK 0001621788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 22,468,503

F1 · ownership.nature: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-19-003700 · doc5.xml · nonDerivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 21,364,655

F1 · ownership.nature: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is a member of the board of managers of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-18-019328 · doc4.xml · derivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 43,056

Underlying: Common Stock · 43,056 shares

Expires 2028-06-30

F1 · derivative.exercise_date: The Reporting Person is a participant in the Issuer's 2018 Stock Option and Incentive Plan and received 43,056 stock options (the "Grant") on July 2, 2018. The Grant shall vest as follows: one-third of the stock options shall vest annually over a period of three (3) years following June 29, 2018 subject to the Reporting Person's continued service to the Issuer through each vesting date.

SEC source: 0000899243-18-017778 · doc4.xml · derivative · entry 7

Satvat Ali J. · CIK 0001621788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 15,347,219 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis.

F3 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis.

F3 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis.

F2 · ownership.nature: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is the chief executive officer and a managing member of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-18-017778 · doc4.xml · derivative · entry 6

Satvat Ali J. · CIK 0001621788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Common Stock · 3,479,198 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis.

F3 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis.

F3 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis.

F2 · ownership.nature: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is the chief executive officer and a managing member of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-18-017778 · doc4.xml · derivative · entry 5

Satvat Ali J. · CIK 0001621788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 2,909,029

Underlying: Common Stock · 397,385 shares

Expires not disclosed

F3 · derivative.exercise_price: Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis.

F3 · derivative.exercise_date: Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis.

F3 · derivative.expiration_date: Upon closing of the Issuer's initial public offering, the preferred stock automatically converted into the Issuer's Common Stock on a 1 to 1.196 basis.

F2 · ownership.nature: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is the chief executive officer and a managing member of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-18-017778 · doc4.xml · derivative · entry 4

Satvat Ali J. · CIK 0001621788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 0

Underlying: Series B Preferred Stock · 332,262 shares

Expires not disclosed

F1 · derivative.exercise_date: Immediately prior to completion of the Issuer's initial public offering, the warrants were automatically exercised for shares of Series B Preferred Stock and such shares acquired were automatically converted into shares of the Issuer's Common Stock on a 1 to 1.196 basis, net of shares of Common Stock withheld by the Issuer to cover the exercise price, resulting in the issuance of 185,623 shares of Common Stock.

F1 · derivative.expiration_date: Immediately prior to completion of the Issuer's initial public offering, the warrants were automatically exercised for shares of Series B Preferred Stock and such shares acquired were automatically converted into shares of the Issuer's Common Stock on a 1 to 1.196 basis, net of shares of Common Stock withheld by the Issuer to cover the exercise price, resulting in the issuance of 185,623 shares of Common Stock.

F2 · ownership.nature: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is the chief executive officer and a managing member of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-18-017778 · doc4.xml · nonDerivative · entry 3

Satvat Ali J. · CIK 0001621788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 19,614,655

F2 · ownership.nature: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is the chief executive officer and a managing member of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-18-017778 · doc4.xml · nonDerivative · entry 2

Satvat Ali J. · CIK 0001621788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 18,614,655

F2 · ownership.nature: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is the chief executive officer and a managing member of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-18-017778 · doc4.xml · nonDerivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director · 10% owner

10b5-1 filing: Not disclosed

Ownership: Indirect · See footnote

Disclosed balance after: 18,826,417

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · ownership.nature: The shares are owned by BridgeBio Pharma LLC. The Reporting Person is the chief executive officer and a managing member of BridgeBio Pharma LLC and may be deemed to beneficially own the shares held by BridgeBio Pharma LLC. The Reporting Person disclaims beneficial ownership of the shares for Section 16 purposes or for any other purpose, except to the extent of his pecuniary interest therein.

SEC source: 0000899243-18-002884 · doc4.xml · derivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2028-02-01

F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.

SEC source: 0000899243-17-013900 · doc4.xml · derivative · entry 1

Satvat Ali J. · CIK 0001621788 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 20,000

Underlying: Common Stock · 20,000 shares

Expires 2027-05-17

F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from May 17, 2017, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.